IRLAB publishes interim report for the period January-June 2024

Gothenburg, Sweden, July 10, 2024 – IRLAB Therapeutics AB (Nasdaq Stockholm: IRLAB A), a company discovering and developing novel treatments for Parkinson’s disease, today announced that the company’s interim report for the period January-June 2024, has been publihed.

IRLAB: Invitation to the interim report for Q2 2024 presentation and webcast

IRLAB’s Phase IIb study of pirepemat can proceed as planned after positive opinion from external safety committee